MRNA | Moderna, Inc. |
Biological Products (no Diagnostic Substances) |
Book value per $ invested | $ 0.78 |
Leverage | 24.53% |
Market Cap | $ 15.4B |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -2.3B |
Margin | -46.38% |
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.